Bachem Holding AG - Asset Resilience Ratio
Bachem Holding AG (BANB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Bachem Holding AG's Asset Resilience Ratio has changed over time. Check BANB strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Bachem Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BANB market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Bachem Holding AG maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Bachem Holding AG Industry Peers by Asset Resilience Ratio
Compare Bachem Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Bachem Holding AG (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Bachem Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CHF0.00 ≈ $0.00 |
CHF1.92 Billion ≈ $2.43 Billion |
-- |
| 2023-12-31 | 8.37% | CHF140.80 Million ≈ $178.01 Million |
CHF1.68 Billion ≈ $2.13 Billion |
-8.76pp |
| 2022-12-31 | 17.12% | CHF236.98 Million ≈ $299.60 Million |
CHF1.38 Billion ≈ $1.75 Billion |
-10.07pp |
| 2021-12-31 | 27.20% | CHF353.17 Million ≈ $446.50 Million |
CHF1.30 Billion ≈ $1.64 Billion |
+26.80pp |
| 2013-12-31 | 0.40% | CHF1.73 Million ≈ $2.19 Million |
CHF438.78 Million ≈ $554.73 Million |
-0.26pp |
| 2008-12-31 | 0.66% | CHF3.01 Million ≈ $3.80 Million |
CHF457.32 Million ≈ $578.17 Million |
-2.46pp |
| 2007-12-31 | 3.12% | CHF13.39 Million ≈ $16.93 Million |
CHF429.07 Million ≈ $542.46 Million |
-9.59pp |
| 2006-12-31 | 12.71% | CHF56.20 Million ≈ $71.05 Million |
CHF442.24 Million ≈ $559.10 Million |
+1.03pp |
| 2005-12-31 | 11.68% | CHF47.69 Million ≈ $60.29 Million |
CHF408.21 Million ≈ $516.09 Million |
-- |
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commerci… Read more